Valuation
- Market cap
- 180,613,000
- Revenue TTM
- $0
- Net income TTM
- $-137,060,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,451,100
- Avg volume
- 1,142,688
- Day's range
- $2.49 – $2.65
- Shares out
- 71,672,000
- Stochastic %K
- 4%
- Beta
- 1.93
- Analysts
- Strong Sell
- Price target
- $7.30
Company profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in sol...
Show more
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 263 4333
- Website
- https://zentalis.com
- Address
- 10275 Science Center Dr., Suite 200, San Diego, United States
Latest news
No headlines yet.
